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Abstract
Background: Correct antibiotic dosing remains a challenge for the clinician. The aim of this study was to assess
the influence of augmented renal clearance on pharmacokinetic/pharmacodynamic target attainment in critically ill
patients receiving meropenem or piperacillin/tazobactam, administered as an extended infusion.
Methods: This was a prospective, observational, pharmacokinetic study executed at the medical and surgical
intensive care unit at a large academic medical center. Elegible patients were adult patients without renal
dysfunction receiving meropenem or piperacillin/tazobactam as an extended infusion. Serial blood samples were
collected to describe the antibiotic pharmacokinetics. Urine samples were taken from a 24-hour collection to
measure creatinine clearance. Relevant data were drawn from the electronic patient file and the intensive care
information system.
Results: We obtained data from 61 patients and observed extensive pharmacokinetic variability. Forty-eight
percent of the patients did not achieve the desired pharmacokinetic/pharmacodynamic target (100% fT>MIC), of
which almost 80% had a measured creatinine clearance >130 mL/min. Multivariate logistic regression
demonstrated that high creatinine clearance was an independent predictor of not achieving the pharmacokinetic/
pharmacodynamic target. Seven out of nineteen patients (37%) displaying a creatinine clearance >130 mL/min did
not achieve the minimum pharmacokinetic/pharmacodynamic target of 50% fT>MIC.
Conclusions: In this large patient cohort, we observed significant variability in pharmacokinetic/pharmacodynamic
target attainment in critically ill patients. A large proportion of the patients without renal dysfunction, most of
whom displayed a creatinine clearance >130 mL/min, did not achieve the desired pharmacokinetic/
pharmacodynamic target, even with the use of alternative administration methods. Consequently, these patients
may be at risk for treatment failure without dose up-titration.
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Introduction
Infection is a well-recognized but persisting problem in
critical care medicine. Sepsis alone is the leading cause
of mortality in non-cardiac intensive care units (ICUs),
with up to 30% of patients dying within 1 month of
diagnosis [1,2]. Adequate antibiotic therapy is one of the
mainstays in treatment, with the emphasis on timely
administration and appropriateness of the spectrum [3].
Optimizing antibiotic exposure is highly important as
well, however, this is proving to be a greater challenge
with recent data showing that antibiotic concentrations
in critically ill patients are highly variable, unpredictable
and commonly sub-optimal [4-7].
Antibiotic dosing regimens are usually determined in
healthy adults with normal physiology or non-critically
ill hospitalized patients. Both the volume of distribution
and clearance are the key determinants of the pharma-
cokinetics of a drug. Unfortunately, pathophysiological
changes in critically ill patients have a profound effect
on both [8].
One of these pathophysiological changes is the devel-
opment of augmented renal clearance (ARC). This is a
phenomenon in which renal elimination of circulating
molecules - including antibiotics - is enhanced. This, in
turn, may lead to sub-therapeutic concentrations of
time-dependent antibiotics such as b-lactam antibiotics,
potentially causing therapeutic failure and selection of
antibiotic-resistant pathogens. Critically ill patients are
at risk for ARC, because of their pathophysiological dis-
turbances, as well as the clinical interventions adminis-
tered [9,10]. The incidence of ARC in critically ill
patients is high and varies between 30% and 85%
depending on the studied population and the definition
of ARC [11-13].
One study has demonstrated the relationship between
renal clearance and low antibiotic concentrations [14], but
the relationship between renal clearance and b-lactam
pharmacokinetic/pharmacodynamic characteristics has
not been evaluated in a large cohort of patients. However,
various pharmacokinetic modeling and simulation studies
have suggested that using extended infusions will prevent
low antibiotic exposure. However, this has never been
tested in a large cohort of relevant patients with ARC.
Therefore, the aim of this study was to assess the influence
of renal clearance on pharmacokinetic/pharmacodynamic
(PK/PD) target attainment when the antibiotic was admi-
nistered as an extended infusion. Both the minimum tar-
get (50% fT>MIC), as well as the target of 100% fT>MIC
which is considered to have higher bactericidal activity
[15] were calculated. Notably this study enrolled patients
without renal dysfunction, defined as an estimated glomer-
ular filtration rate (eGFR) assessed by the MDRD equation
of <80 mL/min.
Materials and Methods
Inclusion and exclusion criteria
The data used for this analysis were collected in two
separate studies performed in the medical and surgical
ICU of Ghent University Hospital, a tertiary care hospi-
tal with a total of 50 adult ICU beds. Both studies were
approved by the Ethics Committee of the Ghent Univer-
sity Hospital (study 1: registration number 2009/543,
study 2: 2010/814). Written informed consent was
obtained from the patient or his/her legal representative.
Adult patients receiving either meropenem (Meronem®,
AstraZeneca) or piperacillin/tazobactam (Tazocin®, Pfizer)
were included if they did not meet exclusion criteria
which included renal dysfunction (defined as an estimated
glomerular filtration rate (eGFR) assessed by the MDRD
equation of <80 mL/min/1.73 m²), absence of an arterial
catheter, or absence of informed consent.
Antibiotic administration
Patients received a loading dose (1 g meropenem or 4.5 g
piperacillin/tazobactam) administered over 30 min, fol-
lowed immediately by the first extended infusion dose of
either antibiotic (1 g meropenem or 4.5 g piperacillin/
tazobactam) every 6 h for piperacillin/tazobactam and
every 8 h for meropenem. Extended infusion doses were
administered over 3 h using a syringe pump via a central
venous catheter.
Sampling and b-lactam assay
The sampling strategy and b-lactam assay used was dif-
ferent in the studies that contributed patients for this
analysis. Twenty patients were included in the first
study, and 41 in the second.
Study 1 (20 patients)
Eight serial plasma concentrations were obtained from
each patient between 24 and 48 h after the initiation of
therapy at baseline and after 1, 1.5, 3, 3.5, 4, 6, and 8 h
for meropenem; at baseline and after 1, 1.5, 3, 3.5, 4, 5,
and 6 h for piperacillin. For each sample, 5 mL of blood
was collected in heparin anticoagulant tubes without
separator gel, via the arterial catheter. Specimens were
centrifuged at 3,000 rpm for 10 min within 30 min of
sampling, and then frozen at -80°C. They were shipped
to the Burns, Trauma & Critical Care Research Centre
of the University of Queensland, Australia for analysis
by a specialized carrier.
The samples were analyzed at the Burns Trauma and
Critical Care Research Centre, University of Queensland.
The plasma concentrations of meropenem and piperacil-
lin were determined by validated high performance liquid
chromatography (HPLC) methods based on a published
procedure that has been optimized for each drug [16].
Sample preparation was by protein precipitation with
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acetonitrile and a wash step with dichloromethane.
Separations were performed on a Waters X-bridge C18
column (2.1 × 30 mm, 2.5 μm) with an acetonitrile: phos-
phate buffer mobile phase (pH 2.5 for meropenem, pH 3
for piperacillin). Detection was by UV at 304 nm (mero-
penem) or 210 nm (piperacillin). The meropenem assay
was linear from 0.2 to 100 mg/L with an imprecision and
inaccuracy <7% at high, medium, and low concentrations.
The piperacillin assay was linear from 0.5 to 500 mg/L
with an imprecision and inaccuracy <10% at high, med-
ium, and low concentrations. Observed concentrations
were corrected for protein binding (piperacillin 30%;
meropenem 2%).
Study 2 (41 patients)
Two plasma samples were obtained per patient (mid-dose
and trough), after administration of at least three doses, to
ensure steady-state. For each sample, 5 mL of blood was
collected in heparin-anticoagulant tubes without separator
gel, via the arterial catheter. The samples were then sent
to the core laboratory of the Dept of Laboratory Medicine
at the Ghent University Hospital, where they were centri-
fuged and frozen immediately upon arrival at -20°C and
were analyzed on the same day.
These samples were analyzed at the toxicology laboratory
of the Department of Laboratory Medicine at the Ghent
University hospital. The plasma concentrations of merope-
nem and piperacillin were determined by validated ultra
high performance liquid chromatography coupled to tan-
dem mass spectrometry (UPLC-MS/MS). Samples were
deproteinized using acetonitrile. After centrifugation, a
portion of the supernatant was diluted and injected on a
Waters BEH C18 column (1.7 μm, 100 × 2.1 mm) kept at
50°C and a gradient elution of water and acetonitrile, both
containing 0.1% formic acid. Compounds were detected
with a Waters Acquity TQD mass spectrometer operating
in positive electrospray ionization using a compound speci-
fic MRM method. The assay was linear from 2 to 80 mg/L
for meropenem, and from 4 to 250 mg/L for piperacillin
with an imprecision and inaccuracy <15% at high, medium,
and low concentrations. Observed concentrations were
corrected for protein binding (piperacillin 30%; merope-
nem 2%).
It should be highlighted that the samples in Study 1
and Study 2 were analyzed using different assays in two
different laboratories. Although a formal inter laboratory
validation was not undertaken, both methods have been
independently validated according to FDA guidelines.
Furthermore, both laboratories monitor the quality of
their analysis by using internal quality controls at three
levels.
Pharmacodynamic analysis
Depending on the study and number of samples avail-
able, different methods were used to calculate the
f T>MIC. When enough samples were available, the
fT>MIC was calculated by observing the time during the
dosing interval that the log-linear least squares regression
analysis intersected the target MICs for Pseudomonas
aeruginosa (16 mg/L for piperacillin and 2 mg/L for mer-
openem based on EUCAST breakpoints [17].
In the case when only two concentrations were avail-
able per patient, another approach was used. One con-
centration (C1) was taken halfway through the dosing
interval, the second sample was a trough concentration
(C2). Using these two concentrations, it is possible to
calculate the elimination constant (equation 1).
C2 = C1 − ek . t (1)
Assuming one compartmental first order kinetics, this
is sufficient to calculate the time within the dosing
interval where the concentration reaches or drops
beneath a certain threshold. In order to investigate if
these two approaches are comparable, the fT>MIC for
the samples from the first study was calculated using
the pharmacodynamic analysis used for the second
study. This was performed for validation purpose only
and was not used for the analyses.
Measurement of creatinine clearance and calculation of
estimates
To calculate a reliable creatinine clearance, urine sam-
ples were taken from a 24-h collection. Creatinine was
measured in both serum/plasma and urine using the
rate blanked, compensated and uncompensated Jaffe
technique, respectively (Modular P and Cobas 6000,
Roche Diagnostics GmbH, Mannheim, Germany). The
creatinine clearance was calculated as follows:
24-h creatinine clearance = Uv × Ucr/(1,440 × Scr),
where Uv is the urinary volume (mL), Ucr the urinary
creatinine concentration (μmol/L), and Scr the serum
creatinine concentration (μmol/L).For assessment of
ARC a cutoff of creatinine clearance ≥130 mL/min was
used [14].
Statistical analysis
The statistical analysis was performed using the statisti-
cal software package IBM-SPSS statistics version 20.0
(IBM Corp., New York, NY, USA). Data are expressed
as median values with interquartile ranges (IQR) for
continuous variables, numbers, and percentages for cate-
gorical variables. In order to identify important covari-
ates, multivariate logistic regression analyses (single
step, forced entry) were conducted with target attain-
ment 100% fT>MIC and target attainment 50% fT>MIC as
dependent variable using the variables which gave a
P value of <0.10 in the univariate analysis. In the case of
covariates which were closely related (such as weight,
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height, and BMI), the one with the most significant
P value was chosen. Goodness of fit was assessed by the
Hosmer-Lemeshow statistic. A receiver operator charac-
teristic (ROC) curve was constructed to examine the
sensitivity and specificity.




Sixty-one patients were included in the analysis. Patient
characteristics on the day of study, and the comparison
between the patients who did and did not reach the PK/
PD target of both 100% fT>MIC and 50% fT>MIC are
shown in Table 1. The median (IQR) creatinine clear-
ance from all patients included in the study was
125 (93-173) mL/min ranging from 55 to 310 mL/min.
Validation of the pharmacodynamic analyses
It was found that the results for both methods used for
determination of fT>MIC were comparable.
Creatinine clearance and PK target attainment
Sixty-one patients were included in the study. One patient
was excluded from the analyses since no urine was col-
lected, as a result of which the creatinine clearance could
not be calculated. Six patients treated with meropenem
had a trough concentration which was lower than the
lower limit of quantification (2 mg/L), which is also the
breakpoint MIC of Pseudomonas aeruginosa. This implies
that these patients did not reach the desired target of
100% fT>MIC, but the exact % fT>MIC could not be calcu-
lated, as this is not possible using only one sample. Two
patients treated with piperacillin/tazobactam could also
not be used for this analysis, because only the trough con-
centration was available, which is not enough to calculate
the exact % fT>MIC . These eight patients were included in
the analysis using the PK/PD target of 100% fT>MIC, but
could not be entered in the analysis using the PK/PD tar-
get of 50% fT>MIC.
Target 100% fT>MIC
Only 33 out of 60 patients (55%), for whom both creatinine
clearance and trough concentrations were available, reached
the PK/PD target of 100% fT>MIC. Patients who did not
attain the predefined PK target (100% fT>MIC) were
younger, had a higher creatinine clearance and a higher
weight (table 1). Twenty-nine patients (48%) had ARC, of
which 22 (76%) did not reach the PK target of 100% fT>MIC.
Figure 1 illustrates the fT>MIC for the patients with and
without ARC. The mean fT>MIC in patients with and with-
out ARC is shown in Figure 2 and was 61% vs. 94% in
patients with and without ARC, respectively (P < 0.001).
The results of the multivariate logistic regression are
shown in Table 2. As the antibiotic administered was
not significantly different between the groups who did
and did not achieve the PK/PD target, this was not
included in the multivariate analysis (P=0.264). Contrary
to creatinine clearance and weight, age was not found to
be significant in the multivariate analysis. The area
under the ROC curve was 0.86 (Figure 3a), with a sensi-
tivity of 81% and a specificity of 81% for predicting tar-
get attainment at 50% probability.
As an illustration of the impact of an increase in crea-
tinine clearance, the probability of achieving the PK/PD
target of 100% fT>MIC was plotted according to the
creatinine clearance using the logistic model for a
patient aged 55 years, weighing 75 kg (Figure 4).
Target 50% fT>MIC
Using the data from these 52 patients for whom both
creatinine clearance and f T>MIC were available, we
found that out of 19 patients displaying ARC, seven
(37%) did not achieve the lower PK/PD target of 50%
fT>MIC (P = 0.002) (Table 1).
The results of the multivariate logistic regression ana-
lysis are shown in Table 3. As the antibiotic adminis-
tered was not significantly different between the groups
who did and did not achieve the PK/PD target, this was
not included in the multivariate analysis (P=0.515). The
area under the ROC-curve was 0.99, with a sensitivity of
95% and a specificity of 100% for predicting target
attainment at 50% probability (Figure 3b). Only creati-
nine clearance was found to be significant in the multi-
variate analysis.
Discussion
In this large observational PK study, using clinical data
from 61 critically ill patients with normal to increased
renal function treated with meropenem or piperacillin/
tazobactam, we found that ARC was associated with a
higher risk of not achieving different PK/PD-targets in
critically ill patients, even when administering these
drugs by extended infusion. This calls into question the
present approach to antibiotic dosing in these patients
and supports use of more aggressive dosing strategies to
minimize the likelihood of clinical failure.
In patients with apparent normal renal function, the
relationship between creatinine clearance and low target
attainment may not come as a surprise as previous studies
have already demonstrated the correlation between creati-
nine clearance and clearance of b-lactam antibiotics
[18-26]. However, to the best of our knowledge, this study
is the first to report the association between creatinine
clearance and the lack of attainment of different PK/PD
targets including the lower target of 50% fT>MIC in
patients with apparent normal renal function receiving
antibiotic therapy administered as an extended infusion.
Using trough antibiotic concentrations, Udy et al. have
demonstrated the association between subtherapeutic
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Table 1 Patient characteristics and comparison between patients who did and did not achieve the PK/PD target of 100% fT>MIC and 50% fT>MIC. Data are
reported as median (interquartile range).
Variable All patients
(n= 60)
PK/PD target (100% f T>MIC)
achieved (n= 33/60) (55%)
PK/PD target (100% f T>MIC) not
achieved (n=27/60) (45%)
P value PK/PD Target (50% f T>MIC)
achieved (n= 43/52) (86%)
PK/PD target (50% f T>MIC) not
achieved (n=7/52) (14%)
P value
Male gender (n, %) 51 (85%) 28 (84%) 23 (85%) 0.721 36 (84 %) 7 (100%) 0.330
Age (years) 56 (48-67) 61 (53-73) 51(30-60) 0.016 60 (52-72) 48 (25-67) 0.054
Weight (kg) 78 (69-90) 75 (65-81) 83 (75-90) 0.014 75 (66-85) 85 (75-90) 0.041
Height (m) 1.75 (1.70-1.80) 1.75 (1.67-1.79) 179 (1.72-1.80) 0.170 1.74 (1.68-1.80) 1.79 (1.75-1.80) 0.098
BMI 25 (22-28) 24 (22-27) 25 (24-29) 0.084 24 (22-27) 25 (25-28) 0.188
SOFA at the day of
study




54 (43-75) 53 (44-79) 56 (41 - 64) 0.623 57 (44-76) 54 (38-59) 0.306
Creatinine clearance
(mL/min)




























b-lactam concentrations and creatinine clearance in select
critically ill patients [14]. In the current study we could
also investigate other targets as we were able to use data
from the entire antibiotic infusion, including the lower
PK-target of 50% fT>MIC. We found that, even when the
dose was administered as an extended infusion, up to 37%
of the patients with ARC did not achieve this minimum
PK/PD target - and may thus be at risk for treatment
failure.
Controversy exists in contemporary literature which PK
target should be aimed for in critically ill patients, as it is
not clear which PK/PD target is associated with highest
probability of reaching clinical cure. Studies have shown
that, depending on the antibiotic, 40% to 70% fT>MIC is
necessary to treat infections [27]. However, recent
research has shown that achieving higher targets may be
associated with a higher probability of reaching clinical
cure. In order to maximize the effect of b-lactam antibio-
tics, it may therefore be necessary to increase the fT>MIC
to 100% or even maintaining the concentration four to
five times the MIC for the entire dosage duration [28-30].
Nevertheless, irrespective of the PK/PD target considered
relevant, increasing creatinine clearance is associated with
lower target attainments.
Although ARC is a relatively new concept in intensive
care medicine, its relevance should not be underesti-
mated. The incidence in critically ill patients is high
[11-13]. Implications for therapy with renally excreted
Figure 1 Histogram % fT>MIC for patients with and without ARC.
Figure 2 Mean % fT>MIC for patients with and without ARC.
Table 2 Multivariate regression model with attainment of
100% fT>MIC as dependent variable.
Attainment of 100 % fT>MIC as dependent
variable





-0.028 0.002 0.972 0.955 0.990
Weight (kg) -0.040 0.114 0.961 0.915 1.010
Age (years) 0.020 0.331 1.020 0.980 1.063
Constant 5.788 0.033 326.34
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drugs are considerable. Case reports have shown that
some patients require up to 6, 8, or even 12 g merope-
nem per day to reach adequate serum concentrations
[31,32]. The effects of renal clearance are important not
only for b-lactam antibiotics, but have also already been
described for other antibiotics, such as vancomycin
[14,33].
This study has a number of limitations. First of all, this
study did not look at clinical outcomes as the data were
drawn from PK studies. Logically, clinical cure and mortal-
ity should be investigated in future validation studies of
altered antibiotic dosing, although these studies should be
even larger than the present study. Second, we have
described renal function at inclusion using the MDRD
which has been shown to underpredict glomerular filtration
rate in some critically ill patients [34,35]. Moreover this
study was only a snapshot, and might not be representative
for the entire course of treatment as creatinine clearance
varies in the course of the disease. Also, this study is a sin-
gle-center study, which only included patients with appar-
ent normal renal function, which limits extrapolation of
these finding to all ICU patients. Finally, we have measured
total drug concentrations with correction for protein bind-
ing based on literature. This is an oversimplification, but
our data show that this approach is acceptable for these
two antibiotics, although is not for more highly protein
bound drugs.
The findings from this study suggest that an even more
sophisticated method of optimization may be necessary
in selected patients - patient-tailored antibiotic therapy -
which is the adaptation of antibiotic therapy to the need
of the individual patient in order to maximize efficacy
Figure 3 ROC curves of the binary logistic model.
Figure 4 Predicted probability of 100% f T>MIC target
attainment.
Table 3 Multivariate regression model with attainment of
50% fT>MIC as dependent variable.
Attainment of 50% fT>MIC as dependent
variable





-0.114 0.045 0.892 0.798 0.997
Weight (kg) -0.035 0.616 0.965 0.841 1.108
Age (years) 0.005 0.906 1.005 0.926 1.096
Constant 24.07 0.07 2.8 × 1010
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and minimize toxicity through therapeutic drug monitor-
ing and dose adaptation. Unfortunately, TDM of b-lactam
antibiotics is currently challenging with long turnaround
times, expensive equipment, logistical problems related to
the instability of the antibiotics in the samples and the
need for well-trained personnel. Efforts to overcome these
limitations, and clinical studies to assess utility in the clini-
cal setting are urgently needed [36].
Conclusions
In conclusion, this study has demonstrated that in criti-
cal care patients receiving meropenem or piperacillin/
tazobactam as an extended infusion, creatinine clearance
is a key factor in the probability of PK/PD target attain-
ment - irrespective if this is 50% or 100% fT>MIC. This
study, which excluded patients with renal dysfunction,
demonstrated that a specific subset of patients is at risk
for PK/PD target non-attainment, more specifically
those patients with increased creatinine clearances, even
if the dose is administered as an extended infusion,
which improves the fT>MIC. By means of multivariate
logistic regression, it was found that a high creatinine
clearance was an independent predictor of not achieving
the PK/PD target, implying that without dose up-titra-
tion, these patients are at risk of treatment failure, even
when extended infusions are used.
Key messages
- Antibiotic concentrations vary greatly in intensive
care patients with normal kidney function.
- The pharmacokinetic/pharmacodynamic target
attainment is dependent on kidney function.
- Patients with augmented renal clearance have a high
probability of target non-attainment, even with the use
of an extended infusion strategy.
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